Propiverine Hydrochloride

DRUG5 trials

Sponsors

APOGEPHA Arzneimittel GmbH, Samsung Medical Center, Lee's Pharmaceutical Limited, Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan, Cairo University

Conditions

Interstitial CystitisOveractive BladderUrinary Incontinence

Phase 2

Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder

CompletedNCT00795925

APOGEPHA Arzneimittel GmbHOveractive Bladder

Start: 2004-10-31End: 2005-12-31Updated: 2008-11-21

Phase 3

Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder

CompletedNCT01512004

Lee's Pharmaceutical LimitedOveractive Bladder

Start: 2010-01-31End: 2011-08-31Updated: 2012-01-25

Phase 4

Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder

CompletedNCT00903045

Samsung Medical CenterOveractive Bladder

Start: 2005-01-31End: 2006-08-31Updated: 2009-05-15

Unknown Phase

Female Patients With Signs of uRgE and Stress Urinary Incontinence Study of Propiverine Hydrochloride

CompletedNCT01942681

Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanUrinary Incontinence

Start: 2013-09-30End: 2015-06-30Updated: 2015-07-15

Effect of Interferential Electrical Stimulation on Pain Perception and Disability Level on Interstitial Cystitis

CompletedNCT03844581

Cairo UniversityInterstitial Cystitis

Start: 2019-01-01End: 2019-02-13Updated: 2019-02-19

Related Papers

Pharmacokinetics and pharmacodynamics of propiverine in children aged between 5 and 10 years with symptoms of overactive bladder.

2010-05-014 citations